<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Myelofibrosis PICOs 2-10</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>Myelofibrosis PICOs</h1>
    </header>

    <div class="container">
        <!-- Mobile Menu Toggle -->
        <button class="menu-toggle">☰ Menu</button>
        
        <!-- Navigation Sidebar -->
        <aside>
            <div class="nav-title">PICO Questions</div>
            <ul class="nav-links">
                <!-- Links will be generated by JS -->
            </ul>
        </aside>
        
        <!-- Main Content Area -->
        <main>
            <!-- Content sections will be generated by JS -->
        </main>
    </div>

    <!-- Original sections (hidden but used for content) -->
    <div style="display: none;">
        <div class="original-section" data-pico="pico2">
            <div class="section">
                <h2>Q2: <strong>Should interferon therapy be used in patients with early/prefibrotic Myelofibrosis?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> Patients with <span class="highlight-population">early/prefibrotic Myelofibrosis</span></li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Interferon therapy</span></li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">No interferon therapy</span></li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Progression to overt MF free survival</li>
                            <li>Leukemia (blast phase transformation) free survival</li>
                            <li>Molecular response</li>
                            <li>Thrombosis risk</li>
                            <li>Symptom response/QOL</li>
                            <li>Adverse events</li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>

        <div class="original-section" data-pico="pico3">
            <div class="section">
                <h2>Q3: <strong>Should JAK inhibitor-naïve, higher-risk (DIPSS intermediate-2 and high) overt Myelofibrosis (primary and post-ET/PV MF) patients without symptomatic splenomegaly and/or inflammatory symptoms be treated with JAK inhibitors vs not?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> <span class="highlight-population">JAK inhibitor-naïve, higher-risk</span> (DIPSS intermediate-2 and high risk) overt Myelofibrosis (primary and post-ET/PV MF) patients <span class="highlight-population">WITHOUT symptomatic splenomegaly and/or inflammatory symptoms</span></li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">JAK inhibitors</span>
                        <ul>
                            <li>Including: ruxolitinib, fedratinib, pacritinib, momelotinib</li>
                        </ul>
                    </li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">No JAK inhibitors</span>
                        <ul>
                            <li>Comparators in studies will include placebo and best available therapy</li>
                            <li>(examples of BAT include hydroxyurea, prednisone, danazol, EPO stimulating agents, thalidomide, lenalidomide)</li>
                        </ul>
                    </li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Leukemia (blast phase transformation) free survival</li>
                            <li>Molecular response</li>
                            <li>Hematological response</li>
                            <li>Adverse effects</li>
                            <li>QOL</li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>

        <div class="original-section" data-pico="pico4">
            <div class="section">
                <h2>Q4: <strong>Should JAK inhibitor-naïve, symptomatic lower-risk (DIPSS low, intermediate-1) overt Myelofibrosis (primary and post-ET/PV MF) patients be treated with JAK inhibitors vs not?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> <span class="highlight-population">JAK inhibitor-naïve, symptomatic lower-risk</span> (DIPSS low, intermediate-1) overt Myelofibrosis (<em>overt primary and post-ET/PV MF</em>) patients
                        <ul>
                            <li>Excluding intermediate-2 or high-risk patients</li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">JAK inhibitors</span>
                        <ul>
                            <li>Ruxolitinib, Fedratinib, Pacritinib, Momelotinib</li>
                        </ul>
                    </li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">No JAK inhibitors</span></li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Leukemia (blast phase transformation) free survival</li>
                            <li>Spleen response/spleen volume reduction</li>
                            <li>Symptom response: Quality of life/Symptom burden</li>
                            <li>Molecular response</li>
                            <li>Adverse events</li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>

        <div class="original-section" data-pico="pico5">
            <div class="section">
                <h2>Q5: <strong>Should JAK inhibitor-naïve, overt Myelofibrosis (primary, post-ET/PV) patients whose primary symptom burden is disease-related anemia be treated with anemia-directed therapy or JAK inhibitor therapy?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> <span class="highlight-population">JAK inhibitor-naïve, overt</span> Myelofibrosis (primary, post-ET/PV) patients with disease-related anemia as the primary symptom
                        <ul>
                            <li>We are excluding early/prefibrotic MF here</li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Anemia-directed therapy</span>
                        <ul>
                            <li>Best available therapy will include erythropoietin, darbepoetin, prednisone, danazol, thalidomide, lenalidomide</li>
                        </ul>
                    </li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">JAK inhibitor therapy</span>
                        <ul>
                            <li>Pacritinib and Momelotinib</li>
                            <li><em>(These JAK inhibitors have potential to improve hemoglobin.)</em></li>
                        </ul>
                    </li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Leukemia (blast phase transformation) free survival</li>
                            <li>Anemia response
                                <ol>
                                    <li>Responses are defined in clinical trials, including rates of transfusion independence, clinical improvement in Hgb (>2g/dl in TI patients)</li>
                                </ol>
                            </li>
                            <li>Symptom burden reduction/QOL</li>
                            <li>Adverse effects</li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>

        <div class="original-section" data-pico="pico6">
            <div class="section">
                <h2>Q6: <strong>Should patients with Myelofibrosis who experience JAK inhibitor-associated anemia be managed with second-line JAK inhibitors, compared to optimization strategies to maintain front-line therapy?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> Patients with <span class="highlight-population">overt Myelofibrosis</span> (overt primary, post-ET/PVMF) experiencing <span class="highlight-population">JAK inhibitor-associated anemia</span>
                        <ul>
                            <li>Will not include early/prefibrotic MF</li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Second-line JAK inhibitors</span></li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">Optimization strategies</span> to maintain front-line therapy</li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Leukemia (blast phase transformation) free survival</li>
                            <li>Anemia response</li>
                            <li>Spleen response</li>
                            <li>Quality of life / Symptom burden</li>
                            <li>Adverse effects</li>
                        </ul>
                    </li>
                </ol>
                <div class="note-box">
                    <strong>Optimization strategies</strong> help manage anemia while maintaining the benefits of JAK inhibitor therapy, avoiding premature switching to second-line treatments. They can include <strong>dose modifications, addition of supportive medications, and transfusion support.</strong>
                </div>
            </div>
        </div>

        <div class="original-section" data-pico="pico7">
            <div class="section">
                <h2>Q7: <strong>Should patients with higher-risk Myelofibrosis (int-2, high) on first-line JAK inhibitor therapy be referred for early transplantation, compared to delayed transplantation after failure of response to JAK inhibitor therapy?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> Patients with <span class="highlight-population">higher-risk Myelofibrosis</span> (DIPSS int-2, high) on <span class="highlight-population">first-line JAK inhibitor therapy</span>
                        <ul>
                            <li>Focus on overt primary MF, also post-ET/post-PV MF</li>
                            <li>Not early/prefibrotic MF</li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Early referral for transplantation</span></li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">Delayed referral for transplantation</span> after loss of response or disease progression on JAK inhibitor therapy</li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Transplant-related mortality</li>
                            <li>Leukemia (blast phase transformation) free survival</li>
                            <li>Relapse</li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>

        <div class="original-section" data-pico="pico8">
            <div class="section">
                <h2>Q8: <strong>Among JAK inhibitor-naïve patients scheduled for transplant, should JAK inhibitor therapy be initiated prior to transplantation?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> <span class="highlight-population">JAK inhibitor-naïve</span> patients <span class="highlight-population">scheduled for transplantation</span>
                        <ul>
                            <li><em>Overt primary and post-ET/PV patients with MF included here</em></li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Initiation of JAK inhibitor therapy</span> prior to transplantation</li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">No initiation of JAK inhibitor therapy</span> prior to transplantation</li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>Transplant-related mortality</li>
                            <li>Relapse</li>
                            <li>Acute GVHD</li>
                            <li>Chronic GVHD</li>
                            <li>Time to engraftment/cumulative incidence of graft failure</li>
                            <li>Infectious complications/viral reactivations</li>
                        </ul>
                    </li>
                </ol>
                <div class="note-box">
                    <strong>Engraftment and graft failure</strong> are opposite outcomes in stem cell transplantation. <strong>Engraftment</strong> is the successful establishment of transplanted stem cells, leading to blood cell production and immune system recovery, typically within 2-4 weeks. <strong>Graft failure</strong> occurs when transplanted cells fail to engraft or are lost after initial engraftment, leading to poor blood cell production and potential need for re-transplantation. The outcome measure <strong>"Time to engraftment/cumulative incidence of graft failure"</strong> assesses both the speed of engraftment and the proportion of patients experiencing failure.
                </div>
            </div>
        </div>

        <div class="original-section" data-pico="pico9">
            <div class="section">
                <h2>Q9: <strong>Should aspirin therapy be used (or not) in all patients with Myelofibrosis?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> All patients with Myelofibrosis, including subgroups:
                        <ul>
                            <li>1) <span class="highlight-population">Prefibrotic</span> 2) <span class="highlight-population">Overt</span> (primary, post-ET/PV MF)</li>
                            <li>2) <span class="highlight-population">JAK2 positive</span> versus <span class="highlight-population">negative</span></li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Aspirin therapy</span></li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">No aspirin therapy</span></li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Arterial thrombosis
                                <ol>
                                    <li>(CVA, TIA, ACS)</li>
                                </ol>
                            </li>
                            <li>Venous thrombosis
                                <ol>
                                    <li>(DVT, PE, abdominal venous thrombosis, cerebral venous thrombosis)</li>
                                </ol>
                            </li>
                            <li>Bleeding complications
                                <ol>
                                    <li>Clinically relevant non-major</li>
                                    <li>Major</li>
                                </ol>
                            </li>
                            <li>Overall survival</li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>

        <div class="original-section" data-pico="pico10">
            <div class="section">
                <h2>Q10: <strong>Should overt Myelofibrosis patients with transfusional iron overload and elevated ferritin be treated with iron chelators or not?</strong></h2>
                <ol>
                    <li><strong>Population:</strong> <span class="highlight-population">Overt Myelofibrosis</span> patients with <span class="highlight-population">transfusional iron overload</span> and elevated ferritin <strong>that will NOT be transplanted</strong>
                        <ul>
                            <li>Will include overt primary and post-ET/PV MF patients</li>
                        </ul>
                    </li>
                    <li><strong>Intervention:</strong> <span class="highlight-intervention">Treatment with iron chelators</span></li>
                    <li><strong>Comparator:</strong> <span class="highlight-comparator">No treatment with iron chelators</span></li>
                    <li><strong>Outcomes:</strong>
                        <ul>
                            <li>Overall survival</li>
                            <li>BP transformation/leukemia-free survival</li>
                            <li>Cardiac complications (e.g., CHF, arrhythmia)</li>
                            <li>Hepatic complications (e.g., cirrhosis, liver failure, hepatocellular carcinoma)</li>
                            <li>Anemia response</li>
                            <li>Adverse effects</li>
                        </ul>
                    </li>
                </ol>
                <div class="note-box">
                    <strong>The main iron chelators used for transfusional iron overload include:</strong>
                    <ol>
                        <li>Deferasirox (Exjade, Jadenu)</li>
                        <li>Deferoxamine (Desferal)</li>
                        <li>Deferiprone (Ferriprox)</li>
                    </ol>
                </div>
            </div>
        </div>
    </div>

    <script src="script.js"></script>
</body>
</html>